COX-2 and SCD, markers of inflammation and adipogenesis, are related to disease activity in Graves' ophthalmopathy

Thyroid

Volumn 17, Issue 6, 2007, Pages 511-517

  Vondrichova, Tereza ^a   De Capretz, Annika ^a   Parikh, Hemang ^a   Frenander, Christofer ^a   Åsman, Peter ^a   Åberg, Magnus ^a   Groop, Leif ^a   Hallengren, Bengt ^a   Lantz, Mikael ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE; CORTICOSTEROID; CYCLOOXYGENASE 2; DEXAMETHASONE; DICLOFENAC; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ADIPOGENESIS; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; DECOMPRESSION SURGERY; DISEASE ACTIVITY; ENDOCRINE OPHTHALMOPATHY; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INFLAMMATION; MOUSE; NONHUMAN; ORBIT RECONSTRUCTION; PRIORITY JOURNAL; PROADIPOCYTE; SWEDEN;

ADIPOCYTES; ADIPOGENESIS; CELL DIFFERENTIATION; CYCLOOXYGENASE 2; DEXAMETHASONE; DICLOFENAC; GENE EXPRESSION; GRAVES OPHTHALMOPATHY; HUMANS; INSULIN; STEAROYL-COA DESATURASE; THIAZOLIDINEDIONES;

EID: 34447515451     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0028     Document Type: Article

References (31)

1. Prabhakar BS, Bahn RS, Smith TJ 2003 Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 24:802-835.
2. Burch HB, Wartofsky L 1993 Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 14:747-793.
3. Char DH 1991 The ophthalmopathy of Graves' disease. Med Clin North Am 75:97-119.
4. Starkey K, Heufelder A, Baker G, Joba W, Evans M, Davies S, Ludgate M 2003 Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use? J Clin Endocrinol Metab 88:55-59.
5. Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS 2002 Stimulation of adipogenesis, peroxisome proliferator activated receptor-gamma (PPAR-γ) and thyrotropin receptor by PPAR-γ agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 87:2352-2358.
6. Smith TJ, Koumas L, Gagnon AM, Bell A, Sempowski GD, Phipps RP, Sorisky A 2002 Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 87:385-392.
7. Tang Q, Otto TC, Lane MD 2003 CCAAT/enhancer-binding protein beta is required for mitotic clonal expansion during adipogenesis. Proc Natl Acad Sci USA 100:850-855.
8. Inuzuka H, Nanbu-Wakao R, Mashuo Y, Muramatsu M, Tojo H, Wakao H 1999 Differential regulation of immediate early gene expression in preadipocyte cells through multiple signaling pathways. Biochem Biophys Res Commun 265:664-668.
9. Lantz M, Vondrichova T, Parikh H, Frenander C, Ridderstråle M, Åsman P, Åberg M, Groop L, Hallengren B 2005 Overexpression of immediate early genes in active Graves' ophthalmopathy. J Clin Endocrinol Metab 90:4784-4791.
10. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE 1998 Cyclooxygenase in biology and disease. FASEB J 12:1063-1073.
11. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM 1995 A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation. Cell 83:813-819.
12. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y 1999 Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908-912.
13. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee KK, O'Rahilly S 1997 Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153.
14. Kim YC, Ntambi JM 1999 Regulation of stearoyl-CoA desaturase genes: role in cellular metabolism and preadipocyte differentiation. Biochem Biophys Res Commun 266:1-4.
15. Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN 2002 Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol Pharmacol 61:7-12.
16. Pinchera A, Wiersinga W, Glinoer D, Kendall-Taylor P, Koorneef L, Marcocci C, Scleusener H, Romaldini J, Niepominiscze H, Nagataki S, Izumi M, Inoue Y, Stockigt J, Wall J, Greenspan F, Solomon D, Garrity J, Gorman C 1992 Classification of eye changes of Graves' disease. Thyroid 2:235-236.
17. Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF 2003 TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol 58:280-287.
18. Kumar S, Bahn RS 2003 Relative overexpression of macrophage-derived cytokines in orbital tissue from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 88:4246-4250.
19. Wang HS, Cao HJ, Winn VD, Rezanka LJ, Frobert Y, Evans CH, Sciaky D, Young DA, Smith TJ 1996 Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. An in vitro model for connective tissue inflammmation. J Biol Chem 271:22718-22728.
20. Han R, Smith TJ 2006 T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin1beta in orbital fibroblasts: implications for the pathogenesis of thyroid associated ophthalmopathy. Endocrinology 147:13-19.
21. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM 1995 15-deoxy-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR-γ. Cell 83:803-812.
22. Kumar S, Coenen MJ, Scherer PE, Bahn RS 2004 Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 89:930-935.
23. Mier A, Weerakoon J, Dandona P 1982 Bilateral abdominal lipohypertrophy after continous subcutaneous infusion of insulin. Br Med J (Clin Res Ed) 285:1539.
24. Fujikura J, Fujimoto M, Yasue S, Noguchi M, Masuzaki H, Hosoda K, Tachibana T, Sugihara H, Nakao K 2005 Insulin-induced lipohypertrophy: report of a case with histopathology. Endocr J 52:623-628.
25. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Blum WF, Wilton P 1995 Insulin-like growth factor I improves height in growth hormone insensitivity: two years' results. Horm Res 44:253-264.
26. Krassas GE, Dumas A, Pontikides N, Kaltsas T 1995 Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol 42:571-580.
27. Dickinson AJ, Vaidya B, Miller M, Coulthard A, Perros P, Baister E, Andrews CD, Hesse L, Heverhagen JT, Heufelder AE, Kendall-Taylor P 2004 Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 89:5910-5915.
28. Stan MN, Garrity JA, Bradley EA, Woog JJ, Bahn MM, Brennan MD, Bryant SC, Achenbach SJ, Bahn RS 2006 Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab (Epub ahead of print).
29. Levin F, Kazim M, Smith TJ, Marcovici 2005 Rosiglitazone-induced proptosis. Arch Ophthalmol 123:119-121.
30. Dorkhan M, Lantz M, Frid A, Groop L, Hallengren B 2006 Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes. Clin Endocrinol 65:35-39.
31. Amemia T 1982 Long-term indomethacin treatment of ophthalmopathies after Basedow disease in general practice. Klin Monatsbl Augenheilkd 181:286-289.